4.7 Review

Mobile Health Advances in Physical Activity, Fitness, and Atrial Fibrillation Moving Hearts

Journal

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 71, Issue 23, Pages 2691-2701

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2018.04.030

Keywords

atrial fibrillation; fitness; cardiovascular disease; mHealth; mobile health; physical activity; prevention

Funding

  1. Amazon
  2. AstraZeneca
  3. Bristol-Myers Squibb
  4. Medtronic
  5. AHA
  6. Apple
  7. Janssen
  8. Cardiva Medical
  9. Boehringer Ingelheim
  10. Abbott
  11. iRhythm
  12. Precision Health
  13. Amgen
  14. Bayer
  15. Gilead
  16. Merck
  17. MyoKardia
  18. Medicines Company
  19. CSL Limited
  20. GlaxoSmithKline
  21. Novartis
  22. Portola
  23. Sanofi

Ask authors/readers for more resources

The growing recognition that health takes place outside of the hospital and clinic, plus recent advances in mobile and wearable devices, have propelled the field of mobile health (mHealth). Cardiovascular disease and prevention are major opportunities for mHealth, as mobile devices can monitor key physiological signals (e.g., physical activity, heart rate and rhythm) for promoting healthy behaviors, detecting disease, and aid in ongoing care. In this review, the authors provide an update on cardiovascular mHealth by highlighting recent progress and challenges with mobile and wearable devices for assessing and promoting physical activity and fitness, and for monitoring heart rate and rhythm for the detection and management of atrial fibrillation. (C) 2018 by the American College of Cardiology Foundation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available